Kornimate/medical-research-clean huggingface dataset:
opioid induced bowel dysfunction in patients undergoing spinal surgery

Conditions: Constipation

Summary: in the present study, the primary aim was to evaluate if oxycodone-naloxone combination compared to oxycodone reduced opioid induced constipation in patients with or without chronic opioid treatment undergoing spine surgery.


Eligibility criteria:
inclusion criteria: * bmi 17 - 35 kg/m2 * elective spine surgery * informed consent obtained exclusion criteria: * allergy to the used drugs * other contraindication to oxycodone medication * no informed consent

Keywords: constipation opioid oxycodone oxycodone-naloxone spine surgery
t-cat laser & cross-linking for keratoconus

Conditions: Keratoconus; Pellucid Marginal Degeneration

Summary: the purpose of this study is to determine whether excimer laser corneal surface ablation (t-cat) can be safely combined with simultaneous corneal collagen cross-linking treatment to produce an improved and stable corneal profile in the treatment of keratoconus.

theoretical framework: corneal ectasia is a relative weakness in the structure of the cornea, which produces a progressive change in its shape with resultant visual distortion. excimer laser surface ablation can be used to re-shape the corneal profile. when the corneal shape is very irregular, corneal topography data gives the best information as to how to re-shape the cornea into a normal profile, and this topography-computer assisted treatment (t-cat) will be used to modulate the surface corneal shape. it is known that collagen cross-linking in the cornea occurs naturally with age, and in diabetes, both of which seem to prevent progressive ectasia. corneal collagen cross-linking with riboflavin has been shown to stabilize the cornea in keratoconus, and prevents progression of the disease. if cross-linking is performed at that moment that the cornea has been re-shaped by t-cat treatment, it should help prevent the corneal thinning resultant from the laser treatment from destabilising the cornea and causing progressive ectasia. purpose: to determine whether excimer laser corneal surface ablation (t-cat) can be safely combined with simultaneous corneal collagen cross-linking treatment to produce an improved and stable corneal profile. design: prospective, interventional trial.

Eligibility criteria:
inclusion criteria: * patients with known keratoconus or pellucid marginal degeneration. exclusion criteria: * age \ 50 years. * minimal corneal pachymetry in eye to be treated of \< 400μ. * evidence of other corneal disease in the eye to be treated (e.g. herpes simplex keratitis). * women who are pregnant or nursing at the time of the initial treatment. * presence of significant central corneal opacity. * patients unwilling to not wear rigid contact lenses in the eye to be operated on for at least one month before baseline examination, and for the first six months post-operatively.

Keywords: keratoconus pellucid marginal degeneration corneal ectasia collagen cross-linking riboflavin uv light excimer laser topography-computer assisted treatment (t-cat) wavelight allegretto laser
place of 68ga-psma-11 pet-ct in the therapeutic decision at the end of the initial staging for high risk prostate cancer patients

Conditions: Prostate Cancer

Summary: several studies have shown a great potential of 68ga-psma pet in high risk prostate cancers patients and a high detection rate than 18f-choline pet. the primary aim of this study is to evaluate the difference of management intent, after the inital staging of high risk prostate cancer patients, with 68ga-psma-11 pet-ct results in comparison of 18f-choline pet-ct results.


Eligibility criteria:
inclusion criteria: * high risk prostate cancer patients with initial tests : ct, bone scintigraphy and 18f-choline exclusion criteria: * contraindication of 68ga-psma pet-ct

Keywords: 68ga-psma pet
effect of remote ischaemic conditioning on clinical outcomes in stemi patients undergoing ppci (condi2/eric-ppci)

Conditions: STEMI; Myocardial Reperfusion Injury

Summary: the purpose of this study is to determine whether remote ischemic conditioning can reduce cardiac death and hospitalization for heart failure at 12 months in patients presenting with a st-elevation myocardial infarction and treated by percutaneous coronary intervention.

the condi2/eric-ppci trial is a randomised controlled clinical trial investigating whether remote ischemic conditioning (ric) can reduce cardiac death and hospitalization for heart failure at 12 months in 5400 patients presenting with a st-elevation myocardial infarction (stemi) and treated by percutaneous coronary intervention (ppci).

Eligibility criteria:
inclusion criteria: 1. onset of stemi symptoms within 12 hours, lasting for more than 30 minutes 2. patients older than 18 years 3. suspected stemi (st-elevation at the j-point in two contiguous leads with the cutoff points: ≥0.2 millivolt (mv) in men or ≥0.15 mv in women in leads v2-v3 and/or ≥0.1 mv in other leads) exclusion criteria: 1. previous coronary artery bypass graft surgery 2. myocardial infarction within the previous 30 days 3. treatment with thrombolysis within the previous 30 days 4. left bundle branch block 5. patients treated with therapeutic hypothermia 6. conditions precluding use of ric (paresis of upper limb, use of an a-v shunt) 7. life expectancy of less than 1 year due to non-cardiac pathology

Keywords: cardioprotection stemi ppci myocardial reperfusion injury myocardial infarct size st-elevation myocardial infarction remote ischaemic conditioning cardiovascular mortality
alkotinib capsule in patients with alk-positive non-small cell lung cancer previously treated with crizotinib

Conditions: ALK-positive Non-small Cell Lung Cancer

Summary: the main purpose of the study is to evaluate safety and efficacy of alkotinib capsule in patients with alk-positive non-small cell lung cancer previously treated with crizotinib.while exploring the relationship between biomarkers and drug efficacy and safety.

the drug being tested in this study is called alkotinib. alkotinib has been demonstrated to benefit people with alk+ nsclc. the study is a non-control study. the study will enroll approximately 104 participants. all participants will take alkotinib 300mg throughout the study. this multi-center trial will be conducted in china. the overall time to participate in this study is 3 years. participants will make multiple visits to the site, and 28 days after last dose of study drug for a follow-up assessment.

Eligibility criteria:
inclusion criteria: * evidence of positive alk. * patients must have demonstrated progression during or after crizotinib treatment. * age 18 years or older at the time of informed consent. * eastern cooperative oncology group performance status (ecog ps) of 0-2 * at least one measurable lesion by response evaluation criteria in solid tumors (recist) version 1.1 (v1.1). * willingness and ability to comply with the trial and follow-up procedures. exclusion criteria: * chemotherapy, radiation therapy, immunotherapy within 4 weeks. * presence of active gastrointestinal (gi) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications. * uncontrolled mass of pleural effusion, pericardial effusion, and peritoneal effusion
effect of glaucoma educators on adherence to prescribed therapeutic regimens in glaucoma patients

Conditions: Glaucoma

Summary: glaucoma is a leading cause of blindness worldwide. non-adherence to glaucoma medication, which may result in loss of vision, is known to be prevalent. available information regarding adherence to prescribed medical therapy suggests that some apparent treatment failures may actually be due to non-adherence. the investigators' specific aim is to conduct a study that will examine the effect of a glaucoma educator intervention on adherence to topical glaucoma therapy. the investigators' hypothesis is that patient education and counseling delivered by a trained glaucoma educator, through both planned visits and telephone contacts, will increase adherence to topical glaucoma therapy.


Eligibility criteria:
inclusion criteria: * diagnosis of primary or secondary open angle glaucoma. * currently on monotherapy drop treatment for glaucoma. * age \> 18 years. * patient has presented for care at the rocky mountain lions eye institute glaucoma center. exclusion criteria: * inability to independently administer eye drops due to physical disability as reported by the patient. * cognitive impairment that would interfere with the ability to self-administer medications as evidenced by a tics score \< 16. * patients who demonstrate \> 80% adherence to glaucoma treatment during the 30 day run-in period. * it is anticipated that the patient will require glaucoma surgery within the next six months.

Keywords: glaucoma patient educator
laser acupuncture for idiopathic bell's palsy

Conditions: Bell Palsy

Summary: bell's palsy is characterized by acute, unilateral onset that compromises function and esthetics, exerting a considerable impact on the social, professional, and psychological aspects of the lives of affected individuals. the objective of this study was to determine whether laser acupuncture therapy could relieve symptoms in patients with bell's palsy.

this study was randomized controlled trial including 360 patients that undergoing bell's palsy. all the patients received oral prednisolone. patients were assigned to the laser acupuncture (la) group, sham la group and control group, with 120 patients in each group. la group and sham la group were received 4 weeks of laser treatment (3 times per week). clinical outcome measure comprised the house-brackmann grading system, sunnybrook facial grading scale (sbfg), facial disability index (fdi) and facial clinimetric evaluation scale (face scale) all the measurements were collected at the baseline, weeks 2, 4, 6, 8, 12 and 24.

Eligibility criteria:
inclusion criteria: * 1. patients diagnosed with idiopathic bell's palsy 2.patients were eligible if they were graded at house-brackmann grade (hb) 3 or higher. exclusion criteria: * 1. serious mental illness or social problems, and neurological disorders, and systemic diseases, such as malignant tumors, and other serious consumptive diseases. 2. planning for pregnancy, those in pregnancy, or those who were lactating. 3.bell's palsy patients who have a disease course of more than 8 weeks.

Keywords: bell's palsy laser acupuncture photobiomodulation rct
effectiveness of chiropractic treatment applied together with ergonomics education in factory workers with neck pain

Conditions: Neck Pain; Work-related Illness

Summary: the aim of this study is to investigate the effectiveness of chiropractic treatment combined with ergonomic training in factory workers with nonspecific neck pain.

the study was planned as a randomized controlled study. workers between the ages of 18-60 who are working in a heat treatment factory in izmir and experiencing non-specific neck pain will be included in the study. the factory workers included in the study will be divided into three by simple random method. the groups will be called chiropractic, placebo and control groups. all participants will be given ergonomic training before the treatment. the chiropractic group will be applied 2 days a week. the placebo group will also be applied sham manipulation 2 days a week. no intervention will be made in the control group. in order to collect data from the participants; visual analog scale, neck disability questionnaire and bournemouth will be used for pain and pain-related dysfunctions, and pittsburgh sleep quality questionnaire will be used to determine sleep quality. these questionnaires will be repeated before starting the study and at the end of the study.

Eligibility criteria:
inclusion criteria: * being between 18-65 years of age, * having neck pain for the last 3 months, * neck pain being 4 or higher on the visual analog scale exclusion criteria: * having undergone surgery in the last 6 months, * not being cooperative, * presence of psychological problems, * neck pain being of radicular or neurological origin, * presence of a systemic or metabolic disease such as cancer, instability in the neck, * vertebro-basilar insufficiency

Keywords: chiropractic occupational diseases
effects of short foot exercise on knee pain, muscle tone, balance, and quality of life in flexible flatfoot patients

Conditions: Flexible Flatfoot; Knee Pain; Balance Impairment; Quality of Life (QOL)

Summary: this study was a clinical trial to investigate the effects of short foot exercise (sfe) and standard physical therapy on knee muscle tone, knee pain and function, balance ability, and quality of life in adults with flexible flat feet and knee pain.

this study aims to determine whether strengthening foot intrinsic muscles through sfe can reduce knee pain, improve muscle function, enhance balance, and improve quality of life in individuals with flexible flatfoot. results may provide evidence-based rehabilitation strategies for managing knee pain in these patients.

Eligibility criteria:
inclusion criteria: * bmi (body mass index): if between 18 and 25 kg/m² * litigation period: if knee pain lasted for more than 6 weeks * navicular drop test: if it was 10 mm or more * numerical assessment scale: if knee pain was 4 or more * health status: if you are a person without health problems and are trying to participate in the experiment exclusion criteria: * history of knee surgery: if you have had knee surgery * treatment history: if you have received physical therapy for knee pain in the 4 weeks before the start of the study * mental status: if you have a psychological disorder that may interfere with your participation in the study * injury status: if you have a current serious injury affecting the lower extremity joints and foot * lower extremity alignment abnormalities and specific conditions: if you have structural flat foot, scoliosis * diseases and other conditions: if you have diabetes, rheumatoid arthritis, or menopause * neurological disorders: if you have experienced a neurological disorder within the past 6 months
a study evaluating the effectiveness of pea compared to placebo for reducing pain severity and duration of migraines.

Conditions: Migraine

Summary: this is a double-blind randomised controlled study to evaluate the effectiveness of orally-dosed palmitoylethanolamide (pea) compared to placebo for reducing pain severity and duration of migraines in otherwise healthy participants aged 18 years and older.


Eligibility criteria:
inclusion criteria: * adults aged over 18 * no recent history (within 2 years) of clinically significant medical conditions including, but not limited to, malignancy (and treatment for malignancy), cardiovascular, neurological, psychiatric, renal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled\*. * participant's full agreement and ability to consent to participation in the study * at least 1 migraine (not headache) episode every 2 months as classified according to the international classification of headache disorders, 3rd edition (ichd3) for migraines published by the international headache society as detailed in section "classification" * access to a computer or smartphone for completing online questionnaires and events. exclusion criteria: * use of long-term medication (unless for controlled medical condition as above) * pregnant, trying to get pregnant or lactating women\^ * chronic past and/or current alcohol use (greater than 14 alcoholic drinks week) * smokers * allergic or hypersensitive to any of the ingredients in the active or placebo formula * use of preventative migraine medication * migraines that have reported: * to occur on 15 or more days/month for more than 3 months, which, on at least 8 days/month, has the features of migraine headache. * a debilitating attack lasting for more than 72 hours. * a seizure * a medical condition will be considered uncontrolled if the participant reports ongoing treatment, a change of either medication type or dose in the past 3 months or any change in symptoms within the past 3 months. * any person suspecting they may be pregnant (e.g. missed period, nausea, fatigue) will be directed to attend their gp for a pregnancy test prior to enrolment in the trial.
understanding and addressing disparities in cancer therapy induced inflammation and associated endothelial dysfunction

Conditions: Breast Cancer

Summary: very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained through experimental studies (e.g., discovery of endothelium-derived relaxing factor/nitric oxide). within the last 10 years technological advancements of -omics approaches, such as rna-sequencing and shotgun proteomics, have dramatically reduced the cost and technical challenge of accessing these tools for discovery-based research. investigators are now able to obtain unbiased datasets showing changes in transcript or protein expression within complex samples. with cost and accessibility of sequencing is no longer being substantial bottleneck, one of major challenges researchers now face is determining how to meaningfully interpret profiles from large datasets. the extensive characterization of molecular pathways impacting inflammatory responses, endothelial function and angiogenesis, the pathway and network analysis tools will be an asset for identification molecular pathways relevant to alterations in microvascular endothelial function. the investigators preliminary studies on only a small number of samples highlights this potential of the proposed approach to lead to identify personalized medicine-based profiles that will predict patients are likely to develop microvascular endothelial dysfunction from ctx.


Eligibility criteria:
inclusion criteria: * adult (≥ 18 years) assigned female sex at birth * diagnosed with invasive non-metastatic breast cancer * receiving neo-adjuvant ctx (or adjuvant ctx and undergoing breast conserving surgery) that includes anthracyclines (such as dox) and/or targeted anti-her2 therapy * able to safely participate in moderate exercise and strength training based on md approval * willing to complete all study activities * self-identifies as black/african american or non-hispanic white exclusion criteria: * unintentional weight loss \> 10% in the past 6 months * current pregnant and lactating patients. must have completed lactation prior to study start * metastatic disease * diagnosed cardiovascular disease as evidenced by cardiomyopathy (reduced regional or global lv contractility), diastolic dysfunction grade 2 or above, symptomatic coronary - artery disease, ejection fraction below 50% * history of prior chemotherapy or targeted h2n treatment received less than 3 years ago * non-english speaking
clinical validation protocol for bci for the communication of patients suffering from neuromuscular disorders.

Conditions: Communication; Neuromuscular Disease

Summary: the objective of this protocol is evaluate the safety and tolerance of a communication system for severely disable patients with myopathies. the system analyses the brain electric activity in real time and converts it into digital commands for a spelling device, which is refered to as the p300 speller in the scientific literature. the secondary objective is to compare the performance of such tool with a more traditional assistive technology for the communication of severely disabled patients : scanner systems.

this is a pilot study for which 15 patients with myopathies will be included. the primary objective of the study is to assess the safety and tolerance of a system for communication named p300 speller. the p3speller is a brain computer interface (bci) that records the brain electric activity with the use of electroencephalography (eeg) and analyzes it in real time in order to identify slight changes generated in relation to a visual stimulation (evoked potentials). the identification of such brain potentials is translated into a digital command for a spelling device. the secondary objective of this study is to compare the efficacy of this spelling device with a more traditional assisitve technology called scanner interface. a scanner interface uses single clicks that can be obtaines with an adequate interface which exploits the remaining muscular activity from a patients. every patient will use each interface (p300 sepller and scanning) with a randomized order. results will bec o,pared in terms of information flow from the patient to the computer expressed in bit rate per minute.

Eligibility criteria:
inclusion criteria: * adult older than 18y.o., diagnosed with neuromuscular disease, stable vital signs and informed consent exclusion criteria: * history of seizure, brain damage, sight or auditory dysfunction, atopic dermatitis, skin hypersensitivity to gold, patient under guardianship, illiterates or not able to cooperate , cognitive dysfunction * steinert disease, merosine negative disease, alpha-dystroglycanopathies
safety and performance of the multi-modal ultrasound tomography (must) device in breast cancer screening

Conditions: Breast Cancer Screening

Summary: this is a single-center, pilot study being conducted to evaluate the safety and performance of the investigational device (must) in detecting malignant lesions in breast tissue.

this is a single-center, prospective, pilot study in which all enrolled subjects will receive the same screening mammography procedures (i.e., 3d mammography plus must). subjects will have between 1 and 4 clinic visits. the number of visits will be based upon the mammography and must findings, and whether additional procedures, such as mri, biopsy, or a repeat must are warranted.

Eligibility criteria:
inclusion criteria: 1. female subject scheduled for routine screening mammogram 2. not currently pregnant or breastfeeding 3. age 40 to 74 years, inclusive 4. weight less than 115 kg 5. able to provide written informed consent 6. willing to comply with study protocol and follow-up recommendations. exclusion criteria: 1. breast implants 2. signs or symptoms of breast disease including changes in the size or shape of breast tissue, palpable lump, bloody or spontaneous clear nipple discharge, and/or eczema of the nipple 3. weeping rash, open wounds, or unhealed sores on the breast 4. bilateral mastectomy or unilateral mastectomy 5. unable to lay prone on the scan table for up to 16 minutes 6. unable to have breast positioned into the must device 7. any breast surgeries in the past 12 months 8. history of cancer diagnosis and/or treatment in the past 5 years. 9. unable or unwilling to undergo mri if indicated

Keywords: tomography ultrasound mammogram breast